These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 24335994)

  • 21. Standard prophylactic enoxaparin dosing leads to inadequate anti-Xa levels and increased deep venous thrombosis rates in critically ill trauma and surgical patients.
    Malinoski D; Jafari F; Ewing T; Ardary C; Conniff H; Baje M; Kong A; Lekawa ME; Dolich MO; Cinat ME; Barrios C; Hoyt DB
    J Trauma; 2010 Apr; 68(4):874-80. PubMed ID: 20386282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment.
    Kruse MW; Lee JJ
    Am Heart J; 2004 Oct; 148(4):582-9. PubMed ID: 15459586
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dosing and monitoring of enoxaparin (Low molecular weight heparin) therapy in children.
    Ignjatovic V; Najid S; Newall F; Summerhayes R; Monagle P
    Br J Haematol; 2010 Jun; 149(5):734-8. PubMed ID: 20346012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of a dosage strategy in patients receiving enoxaparin by continuous intravenous infusion using modelling and simulation.
    Feng Y; Green B; Duffull SB; Kane-Gill SL; Bobek MB; Bies RR
    Br J Clin Pharmacol; 2006 Aug; 62(2):165-76. PubMed ID: 16842391
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Establishment of prophylactic enoxaparin dosing recommendations to achieve targeted anti-factor Xa concentrations in children with CHD.
    Israel EN; Thomas CA; Mastropietro CW
    Cardiol Young; 2018 May; 28(5):715-718. PubMed ID: 29490713
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of Enoxaparin Dosing as a Risk Factor for Bleeding in Lung Transplant Recipients.
    Sofjan AK; Iuppa JA; Bain KB; Deal EN; Witt CA; Hachem RR; Yusen RD
    Ann Pharmacother; 2016 Oct; 50(10):824-31. PubMed ID: 27363845
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enoxaparin dosage adjustment in patients with severe renal failure: antifactor xa concentrations and safety.
    Lachish T; Rudensky B; Slotki I; Zevin S
    Pharmacotherapy; 2007 Oct; 27(10):1347-52. PubMed ID: 17896889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased enoxaparin dosing is required for obese children.
    Lewis TV; Johnson PN; Nebbia AM; Dunlap M
    Pediatrics; 2011 Mar; 127(3):e787-90. PubMed ID: 21321026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low molecular weight heparin in the treatment of venous and arterial thromboses in the premature infant.
    Michaels LA; Gurian M; Hegyi T; Drachtman RA
    Pediatrics; 2004 Sep; 114(3):703-7. PubMed ID: 15342842
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fluctuations of anti-Xa concentrations during maintenance enoxaparin therapy for neonatal thrombosis.
    Lulic-Botica M; Rajpurkar M; Sabo C; Tutag-Lehr V; Natarajan G
    Acta Paediatr; 2012 Apr; 101(4):e147-50. PubMed ID: 22211705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enoxaparin and antifactor Xa levels in pediatric acute burn patients.
    Brown A; Faraklas I; Ghanem M; Cochran A
    J Burn Care Res; 2013; 34(6):628-32. PubMed ID: 24043233
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers.
    Sanderink GJ; Le Liboux A; Jariwala N; Harding N; Ozoux ML; Shukla U; Montay G; Boutouyrie B; Miro A
    Clin Pharmacol Ther; 2002 Sep; 72(3):308-18. PubMed ID: 12235452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-Factor Xa Activity of Prophylactic Enoxaparin Regimens in Critically Ill Patients.
    Helviz Y; Dzigivker I; Raveh-Brawer D; Hersch M; Zevin S; Einav S
    Isr Med Assoc J; 2016 Feb; 18(2):108-13. PubMed ID: 26979004
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An assessment of published pediatric dosage guidelines for enoxaparin: a retrospective review.
    Ho SH; Wu JK; Hamilton DP; Dix DB; Wadsworth LD
    J Pediatr Hematol Oncol; 2004 Sep; 26(9):561-6. PubMed ID: 15342982
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis.
    Sanchez-Pena P; Hulot JS; Urien S; Ankri A; Collet JP; Choussat R; Lechat P; Montalescot G
    Br J Clin Pharmacol; 2005 Oct; 60(4):364-73. PubMed ID: 16187968
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bioactivity of enoxaparin in critically ill patients with normal renal function.
    Gouya G; Palkovits S; Kapiotis S; Madl C; Locker G; Stella A; Wolzt M; Heinz G
    Br J Clin Pharmacol; 2012 Nov; 74(5):806-14. PubMed ID: 23227470
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patients.
    Droege ME; Mueller EW; Besl KM; Lemmink JA; Kramer EA; Athota KP; Droege CA; Ernst NE; Keegan SP; Lutomski DM; Hanseman DJ; Robinson BR
    J Trauma Acute Care Surg; 2014 Feb; 76(2):450-6. PubMed ID: 24458050
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enoxaparin Dose Requirements to Achieve Therapeutic Low-molecular-weight Heparin Anti-factor Xa Levels in Infants and Young Children.
    Wysocki EL; Kuhn A; Steinbrenner J; Tyrrell L; Abdel-Rasoul M; Dunn A; Cloyd C
    J Pediatr Hematol Oncol; 2021 Oct; 43(7):e946-e950. PubMed ID: 33512867
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alternative dosing of prophylactic enoxaparin in the trauma patient: is more the answer?
    Kopelman TR; O'Neill PJ; Pieri PG; Salomone JP; Hall ST; Quan A; Wells JR; Pressman MS
    Am J Surg; 2013 Dec; 206(6):911-5; discussion 915-6. PubMed ID: 24296098
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study.
    Massicotte P; Adams M; Marzinotto V; Brooker LA; Andrew M
    J Pediatr; 1996 Mar; 128(3):313-8. PubMed ID: 8774496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.